[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Phio Pharmaceuticals Corp (PHIO)

Phio Pharmaceuticals Corp (PHIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,243
  • Shares Outstanding, K 11,617
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,700 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta 0.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.23
  • Number of Estimates 2
  • High Estimate $-0.23
  • Low Estimate $-0.24
  • Prior Year $-0.41
  • Growth Rate Est. (year over year) +43.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0400 +2.88%
on 05/08/26
1.3400 -20.15%
on 04/15/26
-0.2300 (-17.69%)
since 04/08/26
3-Month
0.8805 +21.52%
on 02/09/26
1.8800 -43.09%
on 02/13/26
+0.1499 (+16.29%)
since 02/06/26
52-Week
0.8127 +31.66%
on 02/05/26
4.1900 -74.46%
on 11/03/25
-0.7300 (-40.56%)
since 05/08/25

Most Recent Stories

More News
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with Favorable Safety and Pathology DataKey Development Agreements Secured for Nonclinical Toxicology and...

PHIO : 1.0700 (-6.14%)
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Live Presentation and Q&A: Wednesday, April 29, 2026 12 PM EDTKing of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

PHIO : 1.0700 (-6.14%)
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026

Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert...

PHIO : 1.0700 (-6.14%)
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026

Investors and Advisors, and Life Sciences Analysts are Invited to Attend the New York City Event; Virtual Webcast Link Available BelowKing of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio...

PHIO : 1.0700 (-6.14%)
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

A Critical Next Step in Advancing Phio's PH-762 Program to Treat Cutaneous CarcinomasKing of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage...

PHIO : 1.0700 (-6.14%)
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement

Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT)King of Prussia, Pennsylvania--(Newsfile Corp. - March...

PHIO : 1.0700 (-6.14%)
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office

Registration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend...

PHIO : 1.0700 (-6.14%)
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.comKing...

PHIO : 1.0700 (-6.14%)
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update

Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025 Financings and Warrant Exercises Strengthen Balance Sheet...

PHIO : 1.0700 (-6.14%)
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Live Presentation and Q&A: Monday, March 9, 2026 10 AM EDTCEO to Discuss INTASYL Platform and PH-762 Phase 1b Results King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals...

PHIO : 1.0700 (-6.14%)

Business Summary

Phio Pharmaceuticals Corp is focused on developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform. The Company's pipeline consists of RXI-762 and RXI-804 which are in clinical stage. Phio Pharmaceuticals Corp, formerly known as RXi Pharmaceuticals Corporation,...

See More

Key Turning Points

3rd Resistance Point 1.2433
2nd Resistance Point 1.1967
1st Resistance Point 1.1333
Last Price 1.0700
1st Support Level 1.0233
2nd Support Level 0.9767
3rd Support Level 0.9133

See More

52-Week High 4.1900
Fibonacci 61.8% 2.8999
Fibonacci 50% 2.5013
Fibonacci 38.2% 2.1028
Last Price 1.0700
52-Week Low 0.8127

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.